Article info
PDFHow to understand it
Antisense oligonucleotides and other genetic therapies made simple
- Correspondence to Dr Alexander M Rossor; a.rossor{at}ucl.ac.uk
Citation
Antisense oligonucleotides and other genetic therapies made simple
Publication history
- Accepted January 4, 2018
- First published February 17, 2018.
Online issue publication
March 27, 2018
Article Versions
- Previous version (27 March 2018).
- Previous version (27 March 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Other content recommended for you
- Gene therapy for neuromuscular disorders: prospects and ethics
- Spinal muscular atrophy: untangling the knot?
- A current approach to heart failure in Duchenne muscular dystrophy
- The transthyretin amyloidoses: advances in therapy
- Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy
- Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen
- A 2020 centenary perspective on neuromuscular disorders
- HnRNPR strongly represses splicing of a critical exon associated with spinal muscular atrophy through binding to an exonic AU-rich element
- Duchenne muscular dystrophy: genome editing gives new hope for treatment
- Great expectations: virus-mediated gene therapy in neurological disorders